Cell-Free Double-Stranded DNA to DNase Ratio Predicts Outcome after Primary Survived Cardiac Arrest

Cells. 2022 Oct 25;11(21):3367. doi: 10.3390/cells11213367.

Abstract

(1) Double-stranded DNA (dsDNA) and deoxyribonuclease (DNase) as surrogate parameters for accumulating inflammatory hazards are insufficiently studied in resuscitation research. (2) Blood samples of 76 individuals after CA were analyzed 24 and 96 h after ICU admission. Plasma levels of dsDNA, interleukin-8, and monocyte chemoattractant protein-1 and activity of DNase were assessed along with baseline characteristics, intensive care measures, and outcome data. DsDNA/DNase ratio was used as main prognostication parameter. After calculating an optimal empirical cut-off for outcome prediction (death or Cerebral Performance Category ≥3 at 6 months), multivariable logistic regression was applied. (3) Using receiver operating characteristic (ROC) analysis, an area under the curve (AUC) of 0.65 (95% CI 0.50-0.79) was found for dsDNA/DNase after 24 h versus 0.83 (95% CI 0.73-0.92) after 96 h (p = 0.03). The empirical cut-off for dsDNA/DNase ratio after 96 h was 149.97 (Youden). DsDNA/DNase ratio was associated with unfavorable outcome at six months (aOR 1.006, 95% CI 1.0017-1.0094, p = 0.005). In multivariable analysis, the association of dsDNA/DNase ratio independently predicted outcome as a continuous variable (aOR 1.004, 95% CI 1.0004-1.0079, p = 0.029) after adjusting for potential confounders. (4) DsDNA/DNase ratio at 96 h demonstrates good predictive performance for estimating outcome after CA.

Keywords: cardiopulmonary resuscitation; critical care outcomes; deoxyribonuclease; double-stranded DNA; post-cardiac arrest syndrome.

MeSH terms

  • DNA* / blood
  • DNA* / chemistry
  • Deoxyribonucleases* / blood
  • Deoxyribonucleases* / chemistry
  • Heart Arrest* / diagnosis
  • Humans
  • Predictive Value of Tests
  • Prognosis
  • Resuscitation

Substances

  • Deoxyribonucleases
  • DNA

Grants and funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.